Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | NPM1 | P06748 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14100184 | 0.88 | HTR1A (0.47) | HTR1ADRD2SIGMAR1TP53CA1 | |
| SCHEMBL14619102 | 0.84 | EPHX2 (0.50) | HTR1ADRD2SIGMAR1CA1CA2 | |
| SCHEMBL14100186 | 0.83 | SPHK1 (0.53) | HTR1ADRD2CA1CA2CA9 | |
| SCHEMBL15295566 | 0.80 | TP53 (0.56) | HTR1ADRD2TP53RAB9ACA1 | |
| SCHEMBL3785285 | 0.77 | AOC3 (0.45) | SIGMAR1CYP2D6RAB9A | |
| SCHEMBL2233880 | 0.76 | RAB9A (0.57) | RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL658863 | 0.75 | NPC1 (0.56) | RAB9AKMT2A | |
| SCHEMBL12514072 | 0.74 | AOC3 (0.44) | SIGMAR1RAB9ACA1CA2CA9 | |
| SCHEMBL1509554 | 0.74 | LMNA (0.70) | SIGMAR1CYP1A2CYP2D6TMEM97KMT2A | |
| SCHEMBL11148770 | 0.74 | SIGMAR1 (0.57) | SIGMAR1CYP1A2CYP2D6TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | HTR1A 3540/4885DRD2 4846/4885SIGMAR1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.